Reneo Pharmaceuticals
Reneo Pharmaceuticals is a pharmaceutical company that specializes in discovering and developing therapies for rare and potentially life-threatening genetic mitochondrial diseases including Primary Mitochondrial Myopathies (PMMs), Fatty Acid Oxidation Disorders (FAODs) and McArdle disease.
Reneo’s lead asset, REN001, is expected to control a variety of genes involved in mitochondrial activity, hereby improving mitochondrial function.
